Why story becameinfrastructure.
Documentary film built to a clinical standard, with real patients and reviewed science.
That is my disease. That is my life.
A patient watching and thinking that is the whole test. Craft, compliance and budget exist to earn it.
fig. 01 · patient story, in productionDocumentary patient films built to a clinical standard: the years before diagnosis and the decision to join a trial, held on screen without flattening the person.
Lupus, systemic sclerosis, myositis and the rarer vasculitides are invisible from the outside: years of being told the fatigue is stress before anyone names the antibody. The job is to make the mechanism and the burden legible.
A brand film with a patient dropped in for warmth. A sizzle reel borrowing a community's credibility. Communities this small notice both, and the cost lands on the programme.
- Lupus
- Systemic sclerosis
- Myositis
- Vasculitis
- Sjogren
- Rheumatoid arthritis
- Psoriatic disease
- Antiphospholipid syndrome
- IgG4-related disease
- Rare immunology
- Lupus
- Systemic sclerosis
- Myositis
- Vasculitis
- Sjogren
- Rheumatoid arthritis
- Psoriatic disease
- Antiphospholipid syndrome
- IgG4-related disease
- Rare immunology
The conditions we are usually called for.
Why it moves trials.
Recognition
Their own symptoms, described out loud, for the first time.
Understanding
What the therapy does and what the trial asks, plainly.
Trust
Something a clinician can share in ten minutes and stand behind.
Enrolment
A hand goes up. A consent form gets read closely.
Recruitment is the most expensive, most schedule-critical part of a rare-disease trial.
of trials fail to enrol on time, across clinical research as a whole
Perspectives in Clinical Research, 2020
of a development timeline can go on looking for patients
Perspectives in Clinical Research, 2020
Independent research on what video does to understanding and enrolment sits in our evidence dossier, sources and limits attached.
For a condition affecting a few thousand people worldwide, the job is reaching the right handful, spread across a dozen countries, and earning their trust. Scale is beside the point.
Something they can pass to a patient without staking their own credibility. Trust is what a signed consent form is built on.
The material that helps a patient decide also reassures an ethics committee, briefs a new site and answers an investor. That makes it infrastructure.
Three teams own this work.
The strongest programmes put all three in a room at the start, so the whole thing ends up speaking with the same honest voice.
Medical Affairs
Watertight science investigators can use: mechanism explainers and trial overviews that hold their meaning in every market.
Patient Advocacy
Owns the patient relationship. Needs work that is co-created and safe in front of a community that notices the moment it rings false.
Corporate Affairs
Proof for investors, partners and press that real people stand behind the pipeline, told so it survives scrutiny.
Compliance without losing the human.
Guardrails built in from the first draft, while they are still cheap to build.
Review
Sign-off happens on the draft.
Medical and regulatory review at script stage. The MLR questions surface in week one, while they are still cheap to answer.
Consent
The patient is a partner in the work.
Documented and revocable: named channels, territories and usage window, with a route to withdraw. The patient sees their own cut first.
Fair balance
Safety language designed into the script.
Adverse-event and fair-balance language is written into the script and the frame. Where a claim cannot be made, the story never needs it.
Delivery
MLR-ready, with the trail attached.
Deliverables arrive with an audit trail, so review confirms what is already right, and the same master localises for the next market.
Dignity and compliance are the same discipline, pointed at two audiences.
None of it dilutes the emotion. A patient describing their own fatigue inside a reviewed frame lands harder, because everyone watching knows it is real and allowed.
How to brief a studio.
A good brief saves weeks and protects everyone involved.
- 01
Therapeutic and trial context
The disease, the mechanism, the study design, and where the film sits.
- 02
The one thing it must do
Enrol a trial, or explain a mechanism to a sceptical investigator. Built for everything, it persuades no one.
- 03
Who it is for
Patients, caregivers, referring clinicians, sites, investors, and where each will watch.
- 04
Consent and safeguarding
How patients are identified, and who owns the relationship and the boundaries already set.
- 05
The review path
Who signs off at each stage, and the MLR requirements to design in early.
- 06
Languages and reach
The countries and languages in play, so localisation is planned from the start.
- 07
What "true" looks like
The claims you are able to make, and the tone the community expects.
If some is unknown, bring the questions. Half of a good first meeting is deciding what the film should not try to do.
The system outlives the first film.
Most sponsors arrive with one urgent asset and leave with something durable. The second film reuses the first film's grammar and its approvals, and every market localises from the same master.
Questions sponsors ask.
Rare-disease storytelling is documentary film and editorial built to a clinical standard: a real patient’s experience of a condition, the years before diagnosis, the daily reality of living with it, the decision to join a trial, produced so a sponsor can actually use it. It is consented and medically reviewed, and specific enough that another patient watching thinks, that is my disease and that is my life. Testimonial reels and empathy-flavoured marketing fail that test.
Because recognition is the mechanism. A rare-disease audience is small and scattered, so the problem is reaching the right handful of people and earning enough trust that they raise their hand. A patient who has never heard their exact symptoms described out loud stops scrolling when someone on screen describes them precisely. The same film gives a referring clinician something honest to share in a ten-minute appointment and stand behind afterwards.
The guardrails go in from the first draft: medical and regulatory review at script stage, documented and revocable patient consent that names where the film may run and for how long, fair-balance and adverse-event language handled as part of the craft, and MLR-ready deliverables with an audit trail. Before anyone else sees it, we show the patient their own cut.
Seven things: the therapeutic and trial context, the one job the film must do, who it is for and where they will watch it, how patients will be identified and who owns that relationship, the review path and who signs off at each stage, the languages and countries in play, and a clear line on the claims you are able to make. Bring that and the story can be built to a clinical standard from the first draft.